Latest Conference Articles

At Retina Society 2026, Nimesh Patel, MD, discusses how stage 2 ROP before 34 weeks raises the treatment rate and why he urges early referral and a risk-tailored approach to care.

Charles Wykoff, MD, PhD, reviews LUGANO safety and treatment burden data, including a 42% injection reduction with vorolanib insert vs aflibercept, despite a missed primary end point.

Three residents were honored for their leadership, education and research, and patient care contributions in ophthalmology, optometry, and retina.

Subretinal deposits are linked to worse surgical risks in patients with severe aortic stenosis and reduced systemic blood flow.

Mark P. Breazzano, MD, FACS, shares findings from a TriNetX real-world database analysis on how HIV co-infection influences RPR titers in patients with ocular syphilis.

Chhablani reports revakinagene taroretcel-lwey slowed cavitation volume growth and preserved photoreceptor structure in MacTel type 2.

Dilsher S. Dhoot, MD, FASRS, breaks down the Phase 3 SOL-1 results on intravitreal axitinib hydrogel (OTX-TKI) and aflibercept on vision maintenance.

Talisa Forest (de Carlo), MD, discusses how dynamic complement biomarkers track with artificial intelligence-measured geographic atrophy progression.

K. Thiran Jayasundera, MD, MS, FACS, on how patient interviews shaped a tool capturing functional and psychological burdens overlooked by visual acuity.

Christine Kay, MD, discusses 4-year REMAIN data showing durable visual acuity gains with MCO-010, a mutation-agnostic intravitreal optogenetic therapy for advanced retinitis pigmentosa.

EURETINA President Nicole Eter, MD, picks the sessions busy clinicians should follow at the 26th EURETINA Congress in Vienna, from durability data to AI. She also explains why early referral is still the most effective retina treatment.

Study found anti-VEGF therapy was linked to kidney function decline in patients with diabetic retinopathy or retinal vein occlusion.

At ESCRS 2026, Jascha Wendelstein, MD, noted standard ETDRS visual acuity testing misses functional differences between multifocal IOLs that reading-speed testing reveals.

Helena Noguera Nuñez, MD, discusses a prospective study of the TECNIS Odyssey IOL from ESCRS 2026.

Samantha Harding, MD, discusses how ultra-widefield imaging reduces dilation needs and improves diagnosis in paediatric eye care.

At WSPOS Subspecialty Day during the 44th Congress of the ESCRS in London, Mark Bullimore, PhD, MCOptom, shared early trial data suggesting the Stellest 2.0 lens may slow myopic progression twice as fast as the original.

Hove stresses surgeons who prescribe premium lenses or laser surgery to patients should be willing to have those same treatments themselves when needed.

Emami-Naeini previews Retina Society 2026's shift toward AI-derived, quantitative biomarkers in imaging and therapeutics.

Ana Miguel, MD, PhD, explains how artificial intelligence already outperforms experts in glaucoma screening, expands telemedicine access, and reshapes patient conversations.

Giuseppe Giannaccare, MD, PhD, FEBOphth, discusses new data on perioperative low-level light therapy for post-cataract dry eye at ESCRS 2026.

Anat Loewenstein, MD, previews EURETINA 2026 Vienna: the Innovation Spotlight, 17 sessions, symposia, and more.

The 26th EURETINA Congress convenes in Vienna, Austria, from October 1–4, headlined by a new World Retina networking initiative and a revamped Free Paper Forum stage.

At ESCRS 2026, Imane Tarib, MD discusses fostering inclusive ophthalmology workplaces and mentorship for early-career surgeons.

ESCRS 2026 data: patient selection and education may be key to aceclidine (VIZZ; LENZ Therapeutics) persistence.

Alessandro Arrigo, MD, previews an ESCRS 2026 presentation on a patent-pending method that adapts blue light autofluorescence confocal imaging to grade cataracts objectively. The approach yielded reproducible numeric indices that correlated with both expert LOCS III scores and measurable loss of retinal image quality.

Adam Muzychuk, MD, discusses how AI like the Kane formula is improving outcomes, and why he still urges caution over relying on it for clinical decisions.

Hove explains how his own cataract surgery has changed the way he counsels patients about glare, halos, and near vision.

Jai Parekh, MD, MA, FAAO, says AI is poised to transform eye care—from retinal and glaucoma imaging to cataract surgery—without disrupting it.